{"id":"anti-hypertensive-medication","brandName":"Anti-hypertensive Medication -","genericName":"Anti-hypertensive Medication -","companyId":"imperial-college-london","companyName":"Imperial College London","phase":"marketed","status":"active","modality":"Small molecule","aliases":["PR1 Diruetics","PR3 Beta Blockers","PR4 Calcium channel blockers","PR5 ACE inhibitors","PR6 Angiotensin II Receptor Blockers"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Imperial College London is developing an anti-hypertensive medication with a novel mechanism of action, currently in various stages of clinical trials. The drug aims to improve blood pressure management, particularly in uncontrolled hypertension and specific patient populations such as the elderly and those with chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without the specific brand name or additional details, the exact mechanism cannot be determined. Anti-hypertensive medications work through various pathways including ACE inhibition, beta-blockade, calcium channel blockade, or vasodilation. Further information about the specific drug is needed to provide a precise mechanistic explanation.","oneSentence":"This anti-hypertensive medication lowers blood pressure through a mechanism that is not specified in the provided information.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[{"name":"Hypertension"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}